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Metabolic acidosis and vascular 
calcification: Using blueprints 
from bone to map a new venue 
for vascular research
Z Al-Aly1–3
Vascular calcification is an important problem in patients with 
chronic kidney disease. The pathobiology of vascular calcification is 
complex and is intricately related to bone remodeling. Mendoza et 
al. report that experimental metabolic acidosis prevents calcitriol-
induced vascular calcification in uremic animals. To fully understand 
the effect of acidosis on the vasculature, a comprehensive and 
integrated approach that simultaneously examines the effect of 
metabolic acidosis on bone and vasculature is needed.
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Extraosseous or extraskeletal calcifi-
cation, mainly vascular calciﬁcation, 
is being increasingly recognized as an 
important problem in patients with 
chronic kidney disease, diabetes mel-
litus, and chronic inﬂammatory condi-
tions.1 The pathobiology of extraskeletal 
calciﬁcation is complex and involves a 
variety of factors, including derange-
ments in calcium and phosphorus 
homeostasis, increased proinﬂamma-
tory cytokines, increased levels of pro-
calciﬁc moieties, and decreased levels 
of calciﬁcation inhibitors. Vascular cal-
ciﬁcation appears to be a highly regu-
lated process that is also associated with 
increased morbidity and mortality.
Metabolic acidosis is highly preva-
lent in patients with kidney disease.2,3 
Although the effect of metabolic 
acidosis on bone has been investigated, 
its eﬀect on extraosseous calciﬁcation 
and mainly vascular calcification is 
largely unknown. Mendoza and col-
laborators4 (this issue) now show that 
experimentally induced metabolic aci-
dosis prevents extraosseous calciﬁcation 
in a uremic animal model of calciﬁca-
tion. These ﬁndings are important and 
highlight the need for an integrated 
approach to evaluate the eﬀect of meta-
bolic acidosis on bone mineralization 
and extraskeletal calciﬁcation.
Effect of metabolic acidosis on bone
The bony skeleton as an organ system 
contains large amounts of alkaline salts, 
and, in response to chronic metabolic 
acidosis, bone buﬀers hydrogen ions with 
carbonate, subsequently maintaining sys-
temic pH at the expense of liberating bone 
minerals. As a result, chronic metabolic 
acidosis induces net calcium eﬄux from 
bone and a decrease in bone mineral con-
tent. Chronic metabolic acidosis is also 
associated with a signiﬁcant increase in 
urinary calcium and phosphorus excre-
tion and signiﬁcant reduction in proximal 
tubule synthesis of 1,25(OH)2D3, thus 
limiting intestinal calcium absorption 
and subsequently resulting in a negative 
balance of these divalent ions.
Metabolic acidosis induces a net bone 
mineral loss both in vitro and in vivo. 
This happens via two mechanisms, one 
that involves physicochemical mineral 
dissolution and another that involves 
cellular protein and gene regulation. 
Metabolic acidosis affects a repertoire 
of genes and protein expression, leading 
to enhanced osteoclast-mediated bone 
resorption and decreased osteoblast-
mediated matrix protein synthesis and 
alkaline phosphatase activity. Metabolic 
acidosis induces cyclooxygenase-2 mRNA 
and protein in osteoblasts, leading to 
increased production of prostaglandins 
with a resultant increase in the osteoblas-
tic receptor activator of nuclear factor-κB 
ligand (RANKL), which stimulates further 
osteoclast activity. There is also evidence 
to suggest that chronic metabolic acidosis 
alters osteoblast differentiation from 
human mesenchymal stem cells.5
Some studies in patients have sug-
gested that correction of acidosis may 
prevent the progression of secondary 
hyperparathyroidism. A small pro-
spective study examined the eﬀect of 
dialysate bicarbonate concentration on 
the progression of renal osteodystrophy 
in 21 patients on chronic maintenance 
dialysis. Patients were randomized to 
receive dialysis with either conventional 
bicarbonate dialysate (33 ± 2 mmol per 
liter) or dialysate containing additional 
amounts of bicarbonate (7–15 mmol 
per liter) to obtain a predialysis bicar-
bonate concentration of 24 mequiv. 
per liter. Whereas patients assigned to 
the conventional dialysate bicarbonate 
concentration had an average predi-
alysis plasma bicarbonate level of 15.6 
mequiv. per liter, patients assigned to 
the higher dialysate bicarbonate had 
a predialysis bicarbonate level of 24.0 
mequiv. per liter. The study showed 
that after 18 months of follow-up, the 
group of patients assigned to the con-
ventional dialysate bicarbonate concen-
tration had progression of secondary 
hyperparathyroidism as evidenced by 
worsening of bone histomorphometry 
parameters and increased plasma intact 
parathyroid hormone, whereas those 
assigned to higher bicarbonate dialysate 
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experienced no signiﬁcant worsening in 
renal osteodystrophy.6
A cross-sectional retrospective study on 
76 patients with varying degrees of chronic 
kidney disease showed that 10 patients 
(13%) had normal bone histology and bone 
histomorphometry and that those patients 
had on average a higher serum bicarbo-
nate (23 mmol per liter) than patients with 
mild or advanced mixed osteodystrophy, 
who had serum bicarbonate levels below 
20 mmol per liter.7 Another retrospective 
study of 24 patients showed that patients 
with metabolic acidosis often have osteo-
malacia in pure or mixed form and that 
they may be relatively resistant to active 
vitamin D treatment.8
Effect of metabolic acidosis on extra-
osseous calcification
Mendoza and collaborators4 examine 
the effect of metabolic acidosis on 
extraosseous calciﬁcation in ﬁve-sixths-
nephrectomized rats treated with calcitriol 
to induce calciﬁcation. The authors show 
that the addition of NH4Cl to drinking 
water prevents aortic calcium and phos-
phorus accumulation. They make an 
attempt to examine the mechanism of the 
protective eﬀect conferred by metabolic 
acidosis and show that gene expression 
of the sodium-dependent phosphate 
cotransporter Pit-1 is increased and that 
the addition of NH4Cl to drinking water 
abrogates this eﬀect signiﬁcantly.
Bone mineralization and extraskeletal 
calcification: An inverse relationship?
There is growing epidemiologic evidence 
to suggest that there is an inverse rela-
tionship between bone mass and vascu-
lar calciﬁcation. Hak et al.9 examined the 
association between the extent of aortic 
calciﬁcation and metacarpal bone mass 
and density in a cross-sectional study of 
720 postmenopausal women and found 
a graded inverse association. The inves-
tigators in this same study also reported 
on a cohort of 236 women who were 
followed longitudinally for 9 years and 
found that 25% of them had progression 
of aortic calciﬁcation and that the loss in 
metacarpal bone mass and density was 
signiﬁcantly more pronounced in women 
with progression of aortic calciﬁcation.9 
These ﬁndings were echoed in multiple 
other studies that showed an inverse 
correlation between the severity of cal-
ciﬁcation and bone mineral density and, 
in patients followed longitudinally over 
time, a strong graded association between 
the progression of vascular calciﬁcation 
and bone loss.10,11
Similar to ﬁndings in postmenopausal 
women, there seems to be an intimate rela-
tionship between vascular calcium con-
tent and bone mineral content in patients 
with kidney disease. In dialysis patients 
an inverse relationship between arterial 
calciﬁcation and bone density has been 
documented. Furthermore, a high arterial 
calciﬁcation score is associated with bone 
histomorphometry suggestive of low bone 
activity and adynamic bone disease.12 
Recent experimental evidence suggests 
that the bisphosphonates ibandronate and 
etidronate, which inhibit bone resorption, 
prevented medial artery calciﬁcation in 
uremic rats.13 These ﬁndings lend further 
support to a possible link between vascular 
calciﬁcation and bone remodeling.14 The 
prevailing thinking, although not rigor-
ously tested, is that minerals leached out 
of bones, particularly in the uremic set-
ting, ﬁnd their way to extraskeletal sites 
including the vasculature.
The effect of metabolic acidosis on bone 
mineralization and extraskeletal calcifi-
cation: A conundrum
Whereas the eﬀect of metabolic acidosis 
on bone biology is fairly well estab-
lished, the eﬀect of metabolic acidosis on 
extraskeletal calciﬁcation has not been 
previously investigated. Drawing from 
the observations that there is an inverse 
relationship between bone mineral con-
tent and extent of calciﬁcation, it would 
be plausible to hypothesize that metabolic 
acidosis, which contributes to decreased 
mineral bone content, may lead to wors-
ening vascular calciﬁcation. Mendoza and 
collaborators4 take a diﬀerent approach 
in constructing their a priori hypothesis. 
The hypothesis tested by Mendoza et al.4 
rests on the assumption that since the 
molecular ﬁngerprints of calciﬁed vas-
cular tissue share a striking resemblance 
to those of bone tissue, and since the 
process of vascular calciﬁcation seems to 
recapitulate osteogenic bone formation, 
the response of extraosseous calciﬁcation 
to metabolic acidosis may be similar to 
that of bone, and, given that metabolic 
acidosis impairs bone mineralization, it is 
likely to attenuate the calciﬁcation proc-
ess in extraskeletal sites.
The fundamental problem in this hypo-
thetical framework is that it does not 
account for the fate of calcium eﬄux from 
bone in metabolic acidosis. In models pre-
viously tested, metabolic acidosis induces 
a net calcium efflux from bone that is 
accompanied by a signiﬁcant increase in 
urinary calcium excretion and a net nega-
tive balance of calcium. In the uremic ani-
mal model used by the investigators, renal 
handling of calcium could be signiﬁcantly 
impaired. How does the system deal with 
this calcium load? How is it ‘buﬀered’? Is it 
just increased solubility of minerals in an 
acidotic environment? How does the vas-
cular tissue become immune or resistant 
to calciﬁcation? What are the molecular 
mechanisms underpinning this behavior? 
What is the eﬀect of metabolic acidosis on 
bone in experimental uremia? How does 
the addition of active vitamin D modulate 
the relationship?
The study by Mendoza and collabo-
rators4 ushers a new venue for research 
in the ﬁeld of vascular calciﬁcation and 
highlights the need for more studies to 
provide a cohesive understanding of the 
eﬀect of metabolic acidosis on the biology 
of calciﬁcation and the interplay between 
bone and vasculature and its eﬀect on 
health and disease.
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Peeking into the black box: New 
biomarkers for acute kidney injury
JM Thurman1 and CR Parikh2
The development of effective therapies for acute kidney injury (AKI) 
has been hindered by delayed diagnosis in the clinical setting, varying 
definitions of AKI, and limited prognostic information. In a study by 
Portilla et al., elevations in liver fatty acid-binding protein (L-FABP) 
were found to predict AKI in children undergoing cardiac surgery. New 
biomarkers offer the promise of earlier and more accurate diagnosis of 
AKI. Before they can be deemed clinically useful, however, they must 
undergo rigorous validation in multiple cohorts. 
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Preclinical research has revealed a great 
deal about the molecular mechanisms 
that cause acute kidney injury (AKI), 
and potential interventions have been 
identified in rodent models. These 
ﬁndings have not, however, been trans-
lated into eﬀective clinical therapies. 
There are many obstacles to the devel-
opment of therapies for AKI, including 
delayed diagnosis in the clinical setting, 
varying deﬁnitions of AKI, and limited 
tools for characterizing the mechanisms 
of injury in individual patients who may 
have sustained several renal insults.
Because we do not routinely biopsy 
patients with AKI, the severity and 
course of disease are determined almost 
exclusively by changes in the serum cre-
atinine values and urine output. Serum 
creatinine, the more reliable of the two, 
has several limitations and is not an ideal 
biomarker of AKI. It has a wide normal 
range, as its levels are aﬀected by age, 
sex, and race. It is also a poor marker 
of renal reserve, and, most importantly, 
the serum levels increase 1–3 days after 
the episode of kidney insult. To enable 
earlier diagnosis and to provide insight 
into the underlying pathophysiology in 
the individual patient, an eﬀort has also 
been made to identify better biomarkers 
through genomic and proteomic analysis 
of the serum and urine. Such markers 
will probably improve our ability to 
identify the patients at greatest risk of 
developing AKI and also enable earlier 
diagnosis of renal injury. Early interven-
tion has proven critical to the eﬀective 
therapy of many diseases, including 
acute coronary syndromes, cerebral vas-
cular accidents, and head trauma.
Several biomarkers have been investi-
gated in human populations, including 
neutrophil gelatinase-associated lipoca-
lin (NGAL),1–3 interleukin-18 (IL-18),4 
and KIM-1.5 Portilla et al.6 (this 
issue) demonstrate that another urine 
protein, liver fatty acid-binding protein 
(L-FABP), predicts the development of 
AKI (deﬁned as a 50% increase in the 
serum creatinine) in children under-
going cardiac surgery. They found 
that increases in the urinary L-FABP 
within 4 hours after the cardiac surgery 
predicted the subsequent develop-
ment of AKI with an accuracy of 81% 
(area under the curve). Elevations in 
serum creatinine, in contrast, occurred 
between 24 and 72 hours after cardio-
pulmonary bypass.
L-FABP is expressed by proximal 
tubules. Urinary levels of the pro-
tein have previously been shown to 
increase in patients who develop AKI 
after exposure to intravenous contrast 
and to be predictive of progression in 
patients with chronic kidney disease.7 
In a rodent model, the expression of 
L-FABP by the renal tubules increased 
in response to treatment with cispla-
tin.8 Tubular expression of L-FABP 
may, therefore, be a sensitive indicator 
of a number of diﬀerent stressors of the 
tubular epithelial cells.
Pediatric cardiac surgery is an 
ideal clinical setting for performing 
initial ‘bench-to-bedside’ studies in 
development of diagnostic tests. The 
pediatric population is free of comor-
bidities commonly seen in adults. Fur-
thermore, the timing of kidney injury 
(occurring in the intraoperative period) 
is known, and this information can be 
used as a reference point for under-
standing the trend of biomarker levels. 
So far, six biomarkers—NGAL, IL-18, 
KIM-1, NAG, MMP, and now L-FABP—
have been evaluated in the setting of 
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